ArticleJournal of veterinary internal medicine2020
Identification of potential drugs for treatment of hepatic lipidosis in cats using an in vitro feline liver organoid system.
Article in Journal of veterinary internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Liver organoids: From fabrication to application in liver diseases.Frontiers in physiology · 2022Pooled it
- Animal organoids as models for integrated One Health research.One health (Amsterdam, Netherlands) · 2026Review
- Evaluation of Serum Homocysteine and High-Sensitivity Cardiac Troponins in Cats with Hepatic Lipidosis: An Observational Clinical Study.Veterinary sciences · 2026Article
- Perspective: from pathogenesis to treatment in veterinary science through organoid disease modelling.Frontiers in veterinary science · 2026Article
- Veterinary Regenerative Medicine: The Evolving Role of Stem Cell-Based Therapies.Stem cell reviews and reports · 2025Review
- Advancing In Vitro Tools for Oncologic Research in Cats and Dogs.Veterinary sciences · 2025Review
- Improved Differentiation Towards Insulin Producing Beta-Cells Derived from Healthy Canine Pancreatic Ductal Organoids.Veterinary sciences · 2025Article
- Landscape of human organoids: Ideal model in clinics and research.Innovation (Cambridge (Mass.)) · 2024Review
- Adult Animal Stem Cell-Derived Organoids in Biomedical Research and the One Health Paradigm.International journal of molecular sciences · 2024Review
- Companion animal organoid technology to advance veterinary regenerative medicine.Frontiers in veterinary science · 2023Review
- Customized liver organoids as an advancedInternational journal of biological sciences · 2023Review
- Advances in organoid technology for veterinary disease modeling.Frontiers in veterinary science · 2023Review
- Modelling metabolic diseases and drug response using stem cells and organoids.Nature reviews. Endocrinology · 2022Review
- Farm and Companion Animal Organoid Models in Translational Research: A Powerful Tool to Bridge the Gap Between Mice and Humans.Frontiers in medical technology · 2022Review
- Review
- Organoids: a promising new in vitro platform in livestock and veterinary research.Veterinary research · 2021Review
- Organoids to model liver disease.JHEP reports : innovation in hepatology · 2021Review
- Harness Organoid Models for Virological Studies in Animals: A Cross-Species Perspective.Frontiers in microbiology · 2021Review
- Review
- Identification of potential drugs for treatment of hepatic lipidosis in cats using an in vitro feline liver organoid system.Journal of veterinary internal medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundHepatic lipidosis is increasing in incidence in the Western world, with cats being particularly sensitive. When cats stop eating and start utilizing their fat reserves, free fatty acids (FFAs) increase in blood, causing an accumulation of triacylglycerol (TAG) in the liver.
objectiveIdentifying potential new drugs that can be used to treat hepatic lipidosis in cats using a feline hepatic organoid system. ANIMALS: Liver organoids obtained from 6 cats.
methodsEight different drugs were tested, and the 2 most promising were further studied using a quantitative TAG assay, lipid droplet staining, and qPCR.
resultsBoth T863 (a diacylglycerol O-acyltransferase 1 [DGAT1] inhibitor) and 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR; an adenosine monophosphate kinase activator) decreased TAG accumulation by 55% (P < .0001) and 46% (P = .0003), respectively. Gene expression of perilipin 2 (PLIN2) increased upon the addition of FFAs to the medium and decreased upon treatment with AICAR but not significantly after treatment with T863. CONCLUSIONS AND CLINICAL IMPORTANCE: Two potential drugs useful in the treatment of hepatic lipidosis in cats were identified. The drug T863 inhibits DGAT1, indicating that DGAT1 is the primary enzyme responsible for TAG synthesis from external fatty acids in cat organoids. The drug AICAR may act as a lipid-lowering compound via decreasing PLIN2 mRNA. Liver organoids can be used as an in vitro tool for drug testing in a species-specific system and provide the basis for further clinical testing of drugs to treat steatosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.